Introduction
The development of personalized therapy for patients with non-small-cell lung cancer (NSCLC) is likely to result in more effective therapeutic strategies and improved clinical outcomes. In current clinical practice, therapies are administered to nonselected patient populations. The pretreatment detection of responsepredictive markers could allow for a more strategic application of treatment and maximize the therapeutic index. Such individualized treatment is critical to improving outcomes in patients with advanced NSCLC.
In this review, we discuss biomarkers and technologies for the molecular profiling of NSCLC that could be used to guide the clinician toward the most suitable targeted biological therapy or chemotherapy for individual patients. Furthermore, we discuss the identification of NSCLC subpopulations that are most likely to derive a clinical benefit from specific targeted therapies, with the aim of tailoring therapies to individual patients.
Prognostic versus predictive biomarkers
The elucidation of prognostic and predictive biomarkers for the identification of patient subsets, treatment and improved survival of patients with NSCLC has become a major goal of clinical research. Factors such as disease stage, performance status, weight loss and female gender, as well as biological factors such as epidermal growth factor receptor (EGFR) mutations, mutations of the tumor suppressor gene p53 and activation of the Kirsten rat sarcoma (KRAS) oncogenes have significant prognostic and predictive value (Solan and Werner-Wasik, 2003; National Comprehensive Cancer Network, 2008) .
Clinicians should be cognizant of the distinction between prognostic and predictive biomarkers. Prognostic biomarkers are those that provide information about clinical outcome, irrespective of therapy. Such factors are useful to the clinician who must decide whether further treatment is likely to benefit an individual patient. In contrast to prognostic markers, predictive biomarkers are those that are indicative of potential responsiveness to specific therapies or to a group of therapies. In addition, these biomarkers themselves can be molecular targets for drug development (Oldenhuis et al., 2008 ). For example, the level of expression of the excision repair cross-complementing 1 (ERCC1) gene, which has an important function in repairing cisplatin-DNA adducts, was prognostic for improved survival, as well as predictive of reduced response to therapy (Lord et al., 2002) . As tumor progression and response to treatment are determined by numerous codependent factors, a single prognostic biomarker is of limited value. Rather, a multigenetic approach to determining the optimal treatment for individual patients is more likely to be successful. However, this remains a challenge because of the complexity of simultaneously analysing multiple independent parameters (Solan and Werner-Wasik, 2003) . recurrent NSCLC; however, they are most likely to have substantial efficacy only in a small population of patients (Lynch et al., 2004; Shepherd et al., 2005; Reckamp et al., 2008) . Although subset analyses from clinical studies of EGFR TKIs have identified smoking history and Asian ethnicity as two potential clinical features that may predict clinical benefit from these agents, there have been conflicting data as to the predictive value of these parameters. In the ISEL trial of 1692 patients with refractory NSCLC, nonsmokers (hazard ratio (HR), 0.67; P ¼ 0.012) and patients of Asian ethnicity (HR, 0.66; P ¼ 0.01) had a significant survival benefit with gefitinib compared with placebo, whereas no benefit was observed for smokers (HR, 0.92; P ¼ 0.242) or for patients of non-Asian ethnicity (HR, 0.92; P ¼ 0.292), indicating a significant predictive effect for these variables (Thatcher et al., 2005) . Although Asian ethnicity was not a predictor of survival benefit from erlotinib (P ¼ 0.06) in the BR.21 study, never having smoked did show a predictive value (Po0.001). However, on the basis of multivariate analyses, both nonsmoking status (Po0.048) and Asian ethnicity (P ¼ 0.01) were determined to be independent predictive factors for prolonged survival, regardless of treatment (Shepherd et al., 2005) . These data suggest that these factors are more prognostic than being specific predictors of benefit with EGFR TKIs. This is further supported by data from a preplanned subset analysis of the INTEREST trial, which compared the efficacy of docetaxel with that of gefitinib in patients whose disease had progressed or recurred after chemotherapy (n ¼ 1466). In this study, gefitinib and docetaxel resulted in equivalent overall survival (OS) times in subsets, including never-smokers, patients of Asian ethnicity and patients with an adenocarcinoma histology (Douillard et al., 2008; Stinchcombe and Socinski, 2008) . However, given that patients were permitted to cross over to receive gefitinib or docetaxel upon progression, these results may have been reflective of the effect of sequential treatment on OS. Therefore, progression-free survival (PFS) may be a more appropriate parameter for evaluating predictive biomarkers. Indeed, neither Asian ethnicity nor smoking history was found to be predictive of improved PFS with gefitinib (Douillard et al., 2008) .
Given these collective results, it seems unlikely that smoking history and Asian ethnicity could be used to accurately select patients who would benefit specifically from EGFR TKI treatment. In addition, clinical benefits have also been demonstrated with EGFR TKIs in patients with clinical characteristics that are considered to be unfavorable, such as those who smoke, those with squamous histology and men (Thatcher et al., 2005; Clark et al., 2006) . Therefore, selecting patients on the basis of clinical features may not be the best means of driving treatment decisions with EGFR TKIs. Rather, specific biomarkers may be a better parameter for patient selection.
Although some studies have suggested that EGFR mutations are prognostic rather than being predictive factors (Eberhard et al., 2005; Shepherd and Tsao, 2006) , many have shown that they are in fact predictive of favorable clinical outcomes with EGFR TKIs (Bonomi et al., 2007) (see the article by Gazdar (2009) within this issue for a full review of this topic). In four separate studies of EGFR TKIs in patients with metastatic NSCLC, a significantly longer OS was observed in patients harboring EGFR mutations (Cortes-Funes et al., 2005; Han et al., 2005; Mitsudomi et al., 2005; Takano et al., 2005) . In the INTEREST study, EGFR mutation status was identified as the only variable predictor of PFS benefit with gefitinib (Douillard et al., 2008) . Collectively, these studies suggest that EGFR mutation status may be useful in identifying EGFR TKI-responsive subgroups of patients.
First-line gefitinib was evaluated in a trial of chemotherapy-naive patients with advanced NSCLC who harbored EGFR mutations, including primarily exon 19 deletions and L858R. At a median follow-up of 12.3 months, the response rate (RR) was 55%, median PFS was 9.2 months and the projected median OS was 17.5 months . The authors of this study commented that these results compare favorably with historical controls of first-line cytotoxic chemotherapy. More recently, Mok et al. (2008) presented results from the I-PASS trial, which showed that nonsmoking Asian patients with EGFR mutations had a longer PFS with first-line gefitinib than with standard first-line chemotherapy (carboplatin/paclitaxel), whereas those with wild-type EGFR had a better PFS with chemotherapy. Collectively, the results of these studies demonstrate the potential utility of biomarkers such as EGFR mutations for selecting patients who may benefit from first-line EGFR TKIs. In particular, the results from I-PASS advocate a routine analysis for EGFR mutations in nonsmoking Asian patient populations and initial treatment with an EGFR TKI for those carrying EGFR mutations.
Several studies have shown that a high EGFR gene copy by fluorescent in situ hybridization (FISH; that is, FISH positivity) is predictive of a clinical benefit with EGFR TKIs (see the article by Hirsch et al. (2009) within this issue for a full review of this topic). In the ISEL study, FISH positivity, which was reported in 114 of 370 patients, was associated with improved survival benefit with gefitinib compared with low EGFR copy number (HR, 0.61 vs 1.16; P ¼ 0.045). In the BR.21 study, a multivariate analysis showed that FISH positivity was both an independent marker of poor prognosis (HR, 1.93; P ¼ 0.025) and a predictive biomarker for survival benefit of erlotinib therapy (HR, 0.33; P ¼ 0.005) . However, the value of using FISH for the prediction of clinical outcomes with EGFR TKIs must be further evaluated in prospective clinical studies.
Clearly, many patients with NSCLC are initially refractory to EGFR TKIs. The underlying molecular causes of such primary resistance may serve as biomarkers for identifying patients who would be unlikely to respond to EGFR-targeted therapies. One such molecular marker is the KRAS oncogene. This gene is mutated in about 25-30% of lung adenocarcinomas and may be a useful negative prognostic and predictive factor for patients with NSCLC (Huncharek et al., 1999; Pao et al., 2005) . For example, in a meta-analysis of 11 studies including 881 tumor samples from patients with NSCLC, the presence of a KRAS mutation was associated with an almost twofold higher risk of death at 2 years from NSCLC (Huncharek et al., 1999) . Another study, involving 60 lung adenocarcinomas, showed that 24% of lung tumors refractory to gefitinib or to erlotinib were positive for KRAS mutations, whereas mutations were not detected in any drug-sensitive tumor (P ¼ 0.02) (Pao et al., 2005) . These data suggest that the presence of KRAS mutations may predict a poor response to gefitinib and erlotinib in patients with NSCLC, although RRs between tumors with and without KRAS mutations did not reach statistical significance in this study (Pao et al., 2005) . In contrast, the presence of KRAS mutations is an established predictor of nonresponsiveness to cetuximab in patients with metastatic colorectal cancer and is associated with significant decreases in time to progression, PFS and OS (Lievre et al., 2006; Di Fiore et al., 2007; de Reynies et al., 2008; De Roock et al., 2008; Van Cutsem et al., 2008) . The validation of KRAS mutations as a marker of natural resistance to EGFR inhibitors in lung adenocarcinoma will require both retrospective analyses of large randomized studies (for example, the FLEX study of cetuximab) and data from large prospective studies with erlotinib.
Unfortunately, acquired resistance eventually emerges among almost all patients who initially respond to EGFR TKI treatment. The most frequently detected underlying mechanism of acquired resistance is a mutation within the kinase domain of EGFR, T790M, which occurs in approximately 50% of resistant tumors Engelman and Ja¨nne, 2008) . Although it has been speculated that T790M emerges during treatment with EGFR TKIs, a recent study using a highly sensitive allele-specific mutation assay showed that low levels of T790M could be detected in NSCLC tumor samples from TKI-naive patients (Maheswaran et al., 2008) . Although these patients did achieve responses with EGFR TKI treatment, they had a significantly shorter PFS than did those without T790M at baseline (7.7 vs 16.5 months, respectively; Po0.001). These results suggest that T790M may serve as a useful pretreatment biomarker for identifying patients who are unlikely to benefit from erlotinib and gefitinib. A newer class of dual, irreversible EGFR/ HER2 inhibitors (for example, BIBW 2992, HKI-272) has been shown to be effective against T790M in preclinical models (Kwak et al., 2005; Wong, 2007; Li et al., 2008) . Unlike the reversible EGFR TKIs, erlotinib and gefitinib, irreversible TKIs bind to the kinase domain of EGFR covalently. It has been suggested that this covalent binding allows these agents to overcome resistance conferred by T790M (Yun et al., 2008) . Preclinical studies have also shown that resistance emerges less frequently with this class of agents than with the reversible inhibitor gefitinib (Kwak et al., 2005) .
Several clinical trials are currently under way to evaluate these agents in the treatment of patients with advanced NSCLC, including those who have experienced gefitinib or erlotinib failure. The detection of T790M before and during treatment with reversible EGFR TKIs (that is, erlotinib and gefitinib) could prove valuable for tailoring NSCLC treatment regimens in the near future, particularly if the preclinical activity shown against T790M with irreversible EGFR inhibitors, such as BIBW 2992 and HKI-272, translates into clinical efficacy (Kwak et al., 2005; Wong, 2007; Li et al., 2008) .
Amplification of the receptor TK MET accounts for an additional 10-20% of all known causes of acquired resistance to gefitinib and erlotinib (Engelman and Ja¨nne, 2008) . In a gefitinib-sensitive lung cancer cell line, amplification of the MET oncogene activated the erbB3-dependent activation of PI3K (Engelman et al., 2007) . The continued activation of PI3K was shown to confer resistance to EGFR TKIs. The detection of MET amplification may be a useful biomarker for the prediction of resistance to EGFR TKIs in patients with NSCLC. A future tailored treatment approach for patients who present with MET amplification may involve a combination treatment between an EGFR inhibitor and a MET kinase inhibitor.
It is noteworthy that no consensus has been reached on the validity of these biomarkers as predictors of response to EGFR inhibitors in patients with NSCLC. Further prospective clinical studies are necessary to validate individual biomarkers for a predictive value in NSCLC.
Biomarkers for chemotherapy
Several biomarkers are associated with responsiveness to chemotherapy. The expression of thymidylate synthase, which is required for DNA synthesis and cellular proliferation, is associated with tumor proliferation, responsiveness to antifolate inhibitors (for example, pemetrexed) and 5-fluorouracil and with a poor prognosis for patients with NSCLC (Eismann et al., 2006; Huang et al., 2006) . In human tumor samples, the increased expression of thymidylate synthase (>144 copies, related to 10 4 copies of b-actin) predicted resistance to pemetrexed, whereas 81% of tumors expressing p144 copies were sensitive to pemetrexed (Eismann et al., 2006) .
Expression of the ERCC1 gene has also shown a predictive value for benefit with chemotherapy. The association between ERCC1 expression and clinical outcomes with a combination of gemcitabine and cisplatin was evaluated in a study of 56 patients with stage IIIB or IV NSCLC (Lord et al., 2002) . In this study, RR was higher in tumors with a low ERCC1 expression than in tumors with a higher ERCC1 expression (52 vs 36%, respectively), although this difference was not statistically significant. Multivariate analysis also revealed a significantly longer median OS in patients with low levels of ERCC1 mRNA than in patients with high levels of ERCC1 mRNA (62 vs 20 weeks, respectively; P ¼ 0.005). These results suggest that high ERCC1 levels may be predictive of reduced clinical benefit from platinum-based chemotherapy. In contrast, another study of 51 patients with NSCLC who underwent surgical resection showed that a high ERCC1 expression was an independent predictor of prolonged survival .
Ribonucleotide reductase is required for cells to maintain deoxynucleotide pools for DNA replication and repair (Pitterle et al., 1999) . This enzyme is a target for gemcitabine, which interferes with its function. Clinical studies have shown that overexpression of ribonucleotide reductase subunit M1 (RRM1) is associated with reduced survival benefit with gemcitabine/ cisplatin treatment (Rosell et al., 2003 .
A phase II study evaluated molecular analysisdirected, individualized therapy in 60 patients with NSCLC treated with dual-agent chemotherapy with carboplatin, gemcitabine, docetaxel or vinorelbine, on the basis of levels of gene expression of ERCC1 and RRM1 determined by real-time quantitative polymerase chain reaction (Simon et al., 2007) . Patients achieved an RR of 44% and the 1-year OS and PFS rates were 59% (median, 13.3 months) and 14% (median, 6.6 months), respectively. The results from this study compared favorably with those of another phase II study of uncustomized treatment in similar patient populations (RR, 24%; median OS, 6.7 months) (Chiappori et al., 2005) . Collectively, these data suggest that the identification of patients with low expressions of ERCC1 and RRM1 allows for a strategy of individualized chemotherapy in this population, which may result in an improved outcome (Huang et al., 2006; Simon et al., 2007) .
The breast cancer-1 (BRCA-1) gene has an important function in DNA repair and may be a potential predictor of differential chemosensitivity in patients with NSCLC receiving cisplatin. A study of patients with NSCLC treated with gemcitabine and cisplatin showed that patients demonstrating an overexpression of BRCA-1 had decreased survival times (median, 12.7-29.0 months) compared with patients who had low levels of BRCA-1 (median survival not reached) (Taron et al., 2004) . All patients who achieved a complete pathological response had low levels of BRCA-1 expression. However, the predictive value of BRCA-1 levels on treatment efficacy could not be fully assessed because of treatment design. Further studies are necessary to determine the value of BRCA-1 in predicting response to chemotherapy in NSCLC.
The baseline expression level of intracellular adhesion molecule-1 (ICAM-1) may also be a predictive biomarker for responsiveness to chemotherapy. Dowlati et al. (2006) reported results from a prospective correlative assessment of the E4599 randomized trial of carboplatin/paclitaxel with or without the addition of bevacizumab. In this study, plasma VEGF, basic fibroblast growth factor, ICAM-1 and E-selectin were measured in 112 patients enrolled in E4599 at baseline and at week 7 during treatment. Results from this study suggested that low baseline levels of ICAM-1 are predictive of a better OS, regardless of the addition of bevacizumab; 65% of patients with low ICAM-1 levels survived at 1 year compared with 25% of patients with high ICAM-1 levels (P ¼ 0.00005). However, in another study in 57 patients with advanced-stage NSCLC, serum ICAM-1 levels were not predictive of survival benefit with chemotherapy (Guney et al., 2008) . In addition, the possibility that ICAM-1 levels are prognostic cannot be excluded based on the results from Dowlati et al. (2006) Thus, further studies are required to determine the value of serum ICAM-1 as a predictive factor for responsiveness to chemotherapy.
Potential chemotherapeutic biomarkers must be validated in large, prospective trials before their utility in clinical practice can be realized. The results of small trials should be interpreted cautiously. For example, in a small study of 49 patients with NSCLC, Monzo´et al. (1999) demonstrated that mutations in the b-tubulin III gene predicted a lack of response and poor survival with paclitaxel. However, results from a subsequent study suggested that mutations in the b-tubulin gene are likely to be a rare occurrence and are, therefore, unlikely to account for most cases of taxane resistance in NSCLC (Hasegawa et al., 2002) .
Genetic profiling
The genetic profiling of cancers may result in improved clinical outcomes in patients with NSCLC by refining their diagnostic classification. Diagnostic classes may be based on tumor subsets or categories, specific genes that may function as molecular targets for diagnosis or therapy, and genetic profiles that predict responsiveness to therapy or define prognosis (Granville and Dennis, 2005) . Microarray technology allows for the highthroughput parallel analysis of gene expression and is feasible in clinical pathological samples. In a study examining 4966 genes from patients with lung adenocarcinomas, gene-expression profiles revealed high-and low-risk subgroups that differed significantly in their survival times (P ¼ 0.006) (Beer et al., 2002) . The expression of genes conferring a poor prognosis was independent of disease stage, and many of the genes were involved in signaling, cell cycle and growth, transcription, translation and metabolism. This study demonstrates the potential clinical utility of microarray analysis and gene-expression profiling for determining the prognoses and best therapeutic strategies for patients with NSCLC.
A variety of approaches have been developed to handle the large volume of data generated by microarray analyses. Methods for data analysis include hierarchical clustering, principal component analysis and training testing and nearest neighbor analysis (Granville and Dennis, 2005) . Microarray analysis may also be useful in improving the specificity of clinical computed tomographic screening, the prediction of patients at the highest risk for recurrence of disease and drug discovery and development. For example, Potti et al. (2006) described a metagene model that predicted the risk of recurrence in patients with stage IA NSCLC after surgical resection. Furthermore, this model predicted risk with significantly greater accuracy than did standard clinical prognostic factors. Such metagene models could be incorporated into future treatment algorithms, identifying patients who may benefit from adjuvant chemotherapy.
Pharmacogenomics
Pharmacogenomics studies address the way in which variations in the human genome affect individual responses to medications. Pharmacogenomic analysis uses a genome-wide approach and involves a combination of genomics, statistical methods, pharmacology and molecular biology. Pharmacogenomics may not only predict drug response but also identify polymorphisms responsible for drug-related toxicities.
In a pharmacogenomic analysis of the Japan-Southwest Oncology Group study, ethnic differences between patients with NSCLC in Japan and the United States were observed for the allelic distribution of genes influencing the disposition of paclitaxel (Gandara et al., 2007) . Cox modeling revealed genotypic correlations between PFS and the genotypic variant CY-P3A4*1b and between treatment response and the ERCC2 k751q genotype. Tsao et al. (2008) conducted a retrospective analysis of 62 patients with early-stage NSCLC who were enrolled in the JBR.10 trial, and identified a 15-gene expression signature that is prognostic for survival. Using this signature, patients could be grouped according to risk of death: high risk or low risk (HR, 60.1; Po0.0001). Importantly, this model was also predictive of benefit from chemotherapy and showed that chemotherapy significantly reduced the qrisk of death among patients in the high-risk group (HR, 0.27; 95% confidence interval (CI) 0.14-0.51, Po0.0001), whereas low-risk patients did not seem to benefit from chemotherapy (HR, 15.49; P ¼ 0.008).
Proteomics
Proteomics is the systematic determination of protein profiles expressed in cells, plasma or tissue (Granville and Dennis, 2005) . The utility of a proteomic analysis in patients with NSCLC for the prediction of clinical outcomes represents an important evolving area of clinical research and is currently under investigation with respect to the optimal techniques for data analysis (Kikuchi and Carbone, 2007) . Although genomic analysis reveals all of the genes that are expressed by a tumor and the effects of therapy on this gene expression, proteomics describes the corresponding patterns of protein expression (Granville and Dennis, 2005) . Advantages of a proteomic analysis over a genomic analysis include the ability to discern changes in protein expression levels and post-translational modifications directly, but both techniques are limited by their inability to detect very low levels of protein (Granville and Dennis, 2005; Kikuchi and Carbone, 2007) . A major advantage with proteomic analyses is that they can be conducted on serum, plasma, pleural effusions and other bodily fluids (Kikuchi and Carbone, 2007) , making these assays less invasive than those requiring the use of tumor tissue.
The proteomic identification of target proteins involves a two-step process consisting of the separation of proteins by two-dimensional electrophoresis, followed by an analysis of the amino-acid sequence of unique proteins by mass spectrometry (Hirsch et al., 2004; Kikuchi and Carbone, 2007) . Two-dimensional gel electrophoresis separates proteins on the basis of protein charge and molecular weight. This technique allows for the semiquantitative analysis of hundreds of proteins. Individual proteins can then be identified using tandem mass spectrometry in conjunction with available protein sequence databases (Aebersold and Mann, 2003; Webster and Oxley, 2005; Kikuchi and Carbone, 2007) . The application of mass spectrometry to proteomics continues to evolve with the development of new strategies and technologies facilitating quantitative, high-throughput proteomics (Aebersold and Mann, 2003) .
A limited number of clinical studies have used proteomics in the study of lung cancer. In an earlier study of lung adenocarcinoma tissue from 90 patients, Chen et al. (2003) identified high-risk subgroups of patients on the basis of protein expression profiles. Using a quantitative two-dimensional polyacrylamide gel electrophoresis analysis, they identified 46 proteins that were significantly associated with survival. In a recent study of tumor markers to predict response to gefitinib in patients with lung adenocarcinoma, nine proteins that distinguished responders from nonresponders were selected (Okano et al., 2007) . The Eastern Cooperative Oncology Group 3503 study showed that a prediction algorithm incorporating matrix-assisted laser desorption/ionization (MALDI) mass spectrometry facilitated the selection of a subset of patients with NSCLC who were likely to benefit from a first-line treatment with erlotinib (Solomon et al., 2007) . Proteomics has also shown potential for defining pathological differences in subsets of patients with lung cancer (Yanagisawa et al., 2003) , and has been suggested as a potential tool for the early identification of lung cancer (Conrad et al., 2008) .
Practical considerations and challenges
Before biomarker analyses, including genomic and proteomic techniques, can be used daily in the management of patients with NSCLC, a number of technical issues must be resolved. First, all assays need to be validated in large, randomized clinical trials before they can become integrated into routine clinical practice and used reliably to guide treatment decisions in patients with NSCLC. The reliability of using these assays as prognostic and/or predictive factors will depend on resolving a number of technical issues, including standardization of testing, sensitivity and performance of the test, preanalytical variables, such as the size of the tumor specimen and its heterogeneity, proper design and analysis of clinical trials, and cross-validation of results using different assay technologies (Dziadziuszko et al., 2007; Eberhard et al., 2008) . The routine clinical use of immunohistochemical assays is limited by factors affecting the presence and staining intensity of the EGFR protein, such as variations in tissue collection and handling (Atkins et al., 2004) , time from slide preparation, antigen-retrieval techniques, antibody detection (Dziadziuszko et al., 2007) and the quantity and quality of tissue specimens (Eberhard et al., 2008) . Although FISH may be standardized more easily than immunohistochemical assays, barriers exist to routine clinical use, including a lack of expertise in molecular techniques and a lack of experience with dark-field fluorescence microscopy used to assess gene copy number (Eberhard et al., 2008) . False-negative results and artifacts are also problematic in molecular assays. Some sequence changes in the EGFR gene have been shown to be artifacts resulting from the postmortem deamination of cytosine or adenine after formalin fixation (Marchetti et al., 2006) . Several ongoing trials are attempting to clarify the use of these assays for the prediction of response to therapy. In addition, to facilitate the standardization of molecular assays, the Molecular Assays in NSCLC Working Group has been established and provides recommendations for both the standardization of assays and interpretation of data (Eberhard et al., 2008) .
Current challenges in the development and application of proteomics to the treatment of patients with NSCLC include difficulties in the detection of lowabundance proteins because of a limited dynamic range, identification of individual proteins within a complex mixture and data analysis and extraction of all useful information from complex raw data (Hirsch et al., 2004) . Complex biological mixtures of proteins will vary 10-fold in their dynamic range of protein concentrations and contain components that interfere with analysis. Proteins of interest with low copy numbers of 10-1000 per cell may not be detected in proteomic assays because of the presence of highly expressed proteins at >10 000 copies per cell (Hirsch et al., 2004) . Therefore, the accurate identification of an individual protein often requires protein fractionation and removal of interfering substances before the use of two-dimensional polyacrylamide gel electrophoresis and mass spectrometry.
Techniques that are useful for fractionating and purifying proteins of interest include centrifugation, dialysis, size-exclusion filtration, protein precipitation and reverse-phase chromatography. The development of software packages that facilitate the analysis of mass spectrometry data against large protein databases has aided in the extraction of relevant data. Bioinformatic models enable a computer-based compilation of complex biological data and the comparison of gene ontologies between research groups (Ashburner et al., 2000; Patterson, 2003) .
Conclusions
There is a clear need for an individualized approach in choosing an effective and safe therapeutic regimen for patients with NSCLC. Future goals of therapy include matching patients to appropriate diagnostic and treatment strategies to achieve optimal efficacy with no or minimal toxicity. Emerging genomic and proteomic technologies will expand our knowledge regarding the role of genes and proteins in the pathogenesis of NSCLC and will identify biomarkers of predictive and prognostic value. These technologies will allow for an expansion of individual genomic and proteomic roadmaps that will permit the individualization of therapy and ultimately lead to improved treatment strategies for patients with advanced NSCLC. A greater understanding of the molecular basis for response to EGFR TKIs in this malignancy represents a good model for establishing the basis for individualized medicine in routine clinical practice.
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